OS and cumulative incidence of leukemic evolution according to the CPSS-Mol in the learning cohort. (A) OS and (B) cumulative incidence of evolution into AML of patients classified into CPSS-Mol risk groups. The number of patients (N) in each category is reported: low risk group accounted for 22% of patients, intermediate-1 for 29%, and intermediate-2 and high-risk groups for 33% and 16% of patients, respectively.